Iovance stockholders elect all director nominees, approve equity plan and audit ratification at annual meeting

IOVANCE BIOTHERAPEUTICS, INC.

Annual meeting held June 10, 2025; 254,281,338 shares (76.1% of outstanding) represented.
All seven director nominees elected; vote tallies ranged from 97.8M (Countouriotis) to 166.9M (Rothbaum).
Non-binding advisory vote on executive compensation approved: 158.8M for, 14.5M against, 0.8M abstain.
Ratification of Ernst & Young as independent auditor approved: 248.4M for, 4.9M against.
Amendments to 2018 Equity Plan (+12.5M shares) and 2020 ESPP (+1M shares) approved.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.